CLINICAL TRIALS PROFILE FOR TROGLITAZONE
✉ Email this page to a colleague
All Clinical Trials for troglitazone
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00003058 ↗ | Troglitazone in Treating Patients With Liposarcoma | Completed | National Cancer Institute (NCI) | Phase 2 | 1997-06-01 | Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype. |
NCT00003058 ↗ | Troglitazone in Treating Patients With Liposarcoma | Completed | Dana-Farber Cancer Institute | Phase 2 | 1997-06-01 | Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype. |
NCT00116545 ↗ | TART - Troglitazone Atherosclerosis Regression Trial | Completed | Parke-Davis | Phase 2/Phase 3 | 1997-01-01 | The purpose of this study is to determine if troglitazone reduces the progression of early preintrusive carotid atherosclerosis in insulin-requiring diabetes patients. |
NCT00242177 ↗ | Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability | Completed | Takeda Pharmaceuticals North America, Inc. | Phase 1 | 2003-10-01 | The purpose of this study is to determine whether an already FDA approved drug is safe and tolerable in Relapsing Remitting Multiple Sclerosis patients. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for troglitazone
Condition Name
Clinical Trial Locations for troglitazone
Trials by Country
Clinical Trial Progress for troglitazone
Clinical Trial Phase
Clinical Trial Sponsors for troglitazone
Sponsor Name